Agenus Inc(AGEN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:16 PM ET (Korea 10/31 05:16)
Full metrics table
| Index | RUT | P/E | 2.58 | EPS (ttm) | 2.65 | Insider Own | 11.61% | Shs Outstand | 42.6M | Perf Week | 8.06% |
| Market Cap | 0.31B | Forward P/E | - | EPS next Y | -325.23% | Insider Trans | - | Shs Float | 39.9M | Perf Month | -17.89% |
| Enterprise Value | 0.57B | PEG | - | EPS next Q | -0.28 | Inst Own | 38.51% | Short Float | 17.54% | Perf Quarter | -12.53% |
| Income | 0.09B | P/S | 2.33 | EPS this Y | 114.08% | Inst Trans | 17.56% | Short Ratio | 6.2 | Perf Half Y | 78.13% |
| Sales | 0.13B | P/B | - | EPS next 5Y | 32.54% | ROA | 51.42% | Short Interest | 7.00M | Perf YTD | 117.83% |
| Book/sh | -4.67 | P/C | 16.48 | EPS past 3/5Y | 93.99% 82.55% | ROE | - | 52W High | -33.66% ($10.31) | Perf Year | 79.53% |
| Cash/sh | 0.41 | P/FCF | - | Sales past 3/5Y | 5.22% 5.31% | ROIC | - | 52W Low | 152.4% ($2.71) | Perf 3Y | -56.96% |
| Dividend Est. | - | EV/EBITDA | 14.12 | EPS Y/Y TTM | 138.02% | Gross Margin | 95.95% | Volatility(W/M) | 7.23% 7.79% | Perf 5Y | -90.92% |
| Dividend TTM | - | EV/Sales | 4.32 | Sales Y/Y TTM | 30.47% | Oper. Margin | 27.04% | ATR (14) | 0.51 | Perf 10Y | -91.48% |
| Dividend Ex-Date | - | Quick Ratio | 0.34 | EPS Q/Q | 98.53% | Profit Margin | 69.18% | RSI (14) | 46.72 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.34 | Sales Q/Q | 34.36% | SMA20 | -1.09% ($6.92) | Beta | 1.5 | Target Price | $24.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/5 | SMA50 | -9.86% ($7.59) | Rel Volume | 0.5 | Prev Close | $7.09 |
| Employees | 81 | LT Debt/Eq | - | EPS/Sales Surpr. | -122.22% 1.47% | SMA200 | 38.76% ($4.93) | Avg Volume(3M) | 1.13M | Price | $6.84 |
| IPO | 2000/2/4 | Option/Short | Yes/Yes | Trades | 3787 | Volume | 564,423 | Change | -3.53% |
🧬 Agenus is a US clinical-stage biotech company focused on immuno-oncology. Building on its antibody-based immune checkpoint modulators and proprietary immune-enhancing (adjuvant) technology, the company is developing novel drug candidates targeting a range of solid tumors. Since its founding in 1994, Agenus has continued its research into cancer therapeutics leveraging immune mechanisms.
Over the past 1 year, roughly in the middle
34% below its 1-year high.
Traded less than usual. That is 50% of its average volume.
Next earnings report: November 5
6 days to go.
AGEN makes money but has a weak balance sheet
Of every $100 in sales, $27.04 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +114.1% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $1,412. Peers typically go for $2,000. Compared with its own 1-year average, it is 10% cheaper now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -90.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 38.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #261 of 595 in the industry
Based on market cap of $309M.
FAQ
What kind of company is AGEN?
AGEN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AGEN?
The market cap of AGEN is approximately $309M, ranking 3,609 within its sector.
What is the P/E ratio of AGEN?
AGEN has a P/E ratio of approximately 2.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for AGEN?
AGEN has recorded a 52-week high of $10.31 and a low of $2.71.
